New York, USA - Clickbank is a very successful company that consists in an online marketplace containing any kind of digital products, it is a Keynetics subsidiary and it is headquartered in Boise, Idaho; providing services in more than 200 countries all over the globe using the internet.

Clickbank generated about 350 million dollars of yearly revenue (2011) and it managed to draw about one million and a half affiliate marketers, paying its vendors and affiliates about 1.8 billion dollars, processing around 35.000 transactions a day.

The only career where you can choose to dedicate part-time or full-time hours to building your Clickbank business on a flexible schedule and on your own terms. Clickbank is the flexible opportunity based on helping people to make money with Clickbank affiliate marketing.

It’s time to take the first step towards the life you deserve. No one can deny that Clickbank affiliate marketing is a very profitable business; all you need to do is to know how to use it and make it work for you. When it comes to online services, there are many competitors and websites providing the same services. Even though Clickbank has a considerable number of competitors offering similar services, Clickbank stands out from the crowd and that’s why I recommend that you use it. In this chapter I am going to explain you what Clickbank is, and why you should use it.

There are many sources of business opportunity. What is the difference between Clickbank affiliate marketing and other sources of business opportunity? To make money with Clickbank you need to change your habits, to change your habits you need the support of people who have already made it. Without daily motivation and advice, people give up as soon as they make a mistake. Because they do not know whether they are on the right track or not. Don't let that happen to you. Imagine: What happened to the last time you saw that after 30 days you did not earn anything in clickbank and are still at a loss? You gave up. What would happen if you had many people besides you who could tell you that it happened to them, but they went on and eventually succeeded. Would you then continue or quit? Well you would go on.

Understanding this, with the purchase of "Clickbank Affiliate Mastery Training", our team also offers you everything else you need for your Clickbank business.

Simply "Clickbank Affiliate Mastery Training" is one complete Clickbank course with 12 modules and 10 best Clickbank campaigns that will help you build your Clickbank business from scratch.


About the Company:

Clickbank is a very successful company that consists in an online marketplace containing any kind of digital products, it is a Keynetics subsidiary and it is headquartered in Boise, Idaho; providing services in more than 200 countries all over the globe using the internet.

Clickbank generated about 350 million dollars of yearly revenue (2011) and it managed to draw about one million and a half affiliate marketers, paying its vendors and affiliates about 1.8 billion dollars, processing around 35.000 transactions a day

Contact Information:

Contact Person Name: Vladislav Aleksic

Company: Clickbank


Phone: 0643515821

Location: New York, USA




On 23rd August 2020, the Defi leaderboard platform named Defipulse has seen an impressive record of 6.75B of Eth locked in the on-going Defi project. This is an all-time high recorded by Defipulse, and many doubt it is already at its ATH peak, however, in comparison to the total centralized cryptos market cap of nearly 400B, this number is partially insignificant. 

In terms of the decentralization, transparency, and financial future growth, Defi shows a better potential in comparison to centralized financial projects. Because of that, lately, Defi has been rising rapidly and become a real promising scenario of blockchain field in the upcoming time. 

Due to the Covid pandemic, the whole world economy has seen a massive number of centralized interferes with the financial business. For example, on 10th June 2020, the Federal Reserve official held rates to zero in the USA, after that we have seen a financial "exodus" of bankers and savers from the centralized financial systems to a better one like Real Estate, logistic or decentralized projects.

This is why Defi has its own advantage and attraction over the centralized financial institution, meanwhile, the centralized institutions require a lot of physical infrastructure and human works. By contrast, Defi shows better global accessibility and scalability, all the infrastructure and procedures are on a smart contract. Defi is worldwide-used and transacted freely at people's fingertips, no borders.

For projects such as Aave, Compound, or even Makerdao, who offers lending and borrowing service, people can instantly lend or borrow with the collateralization. Paradefi is a lending and future derivative Defi platform in which offers people access to lending and borrowing service based on the Ethereum smart contract. 

Paradefi is also the first Defi platform having both fiat on-ramp and off-ramp integration to over 46 currencies worldwide, and more currencies will be adopted to the platform.

Moreover, Paradefi offers convenient loan facilities, curve platform, portfolio management dashboard, and governance testnest on Ropsten, al the hard works have been done even before the initial decentralized offerings. 

Paradefi dApp is fully-equipped with all the necessary decentralized features on a user-friendly interface. In terms of real-data management, Paradefi is also one of the rare projects integrating with Chainlink's Oracles Solution to bring the real-data into the Paradefi ecosystem. Last but not least, the Paradefi team is also proud to be the first Defi having incentive teller program in which encourages people to spread the network worldwide and gain mass adoption to the platform

"In Paradefi Ecosystem, every citizen is a digital bank teller, by scaling the platform, people can be benefited greatly from that, this is how our outstanding platform performs", said by Carlson

Get more information, please visit


  • Biotech Acceleration Focused on Licensing and Acquiring New Assets.
  • Rapid Innovation & Partnerships with Established Bio-Industry Leaders.
  • FDA Approved Non-Opioid Pain-Med Strontium89 Coming to Global Market.
  • Production of Uttroside-B, a Novel Chemotherapeutic for Liver Cancer.
  • Virus-Agnostic Therapeutic for COVID-19, Influenza, Related Diseases and Future Viral Pandemic Outbreaks.

Q BioMed, Inc. (OTCQB: QBIO), is a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. QBIO is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need?.

QBIO aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. QBIO believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets.

QBIO launched its FDA approved, non-opioid drug Strontium89, which relieves bone pain from cancer metastases, in February 2020. Strontium89 is also approved for sale in 21 other countries. The QBIO robust clinical pipeline is expected to produce growing revenues for the company and value infection points for investors.

  • Strontium89 Will be Available in September 2020 Through Named Patient Program for Bone Metastases Pain Palliation in EU and Globally

On August 11th QBIO announced launching a Named Patient Program for its non-opioid bone metastases pain palliation drug, Strontium89 (Strontium Chloride Sr-89 Injection, USP). The Named Patient Program will be available to physicians and patients in the EU and throughout the world, and will be facilitated by Caligor Coghlan Pharma Services (CCPS).

Strontium89 is indicated for the treatment of painful skeletal metastases caused by cancer, and is agnostic of the primary tumor. Common primary tumors that metastasize to the bone include prostate, breast, lung, as well as others. In several multicenter, placebo-controlled trials in cancer patients with pain from bone metastases, pain relief occurred in more patients treated with a single injection of Strontium89 than in patients treated with an injection of placebo. Strontium89 is administered intravenously once every three months and for some patients can reduce or even eliminate the need for opioid analgesics; pain relief lasts from 2 - 5 months in most patients.

Over ten million people around the world suffer from pain associated with metastatic cancer in the bone and may benefit from Strontium89. For nearly two years, there has been little to no access to this vital therapy, after manufacturing ceased in December of 2018. QBIO is pleased that the Named Patient Program will ensure immediate global patient access to an important therapy for this patient population. In the meantime, QBIO is actively pursuing full regulatory and marketing approval for Strontium89 in all major markets worldwide.

  • Scaled Up Production of Uttroside-B, a Novel Chemotherapeutic for Liver Cancer, in Preparation for IND Filing

On July 22nd QBIO and Chemveda Life Sciences announced continued collaboration on Uttroside-B, a chemotherapeutic that has shown remarkable potential efficacy as a treatment for liver cancer. While focused on its commercial rollout of Strontium89, this drug development program will advance another important asset in the QBIO portfolio towards monetization. The efficacy of Uttroside-B, a potent saponin, against liver cancer was demonstrated in a preclinical study published in the November 2016 issue of Scientific Reports, Nature journal.

  • Partnership to Deliver Virus-Agnostic Therapeutic for COVID-19, Influenza, Related Diseases and Future Viral Pandemic Outbreaks

On June 30th QBIO issued a Shareholder Update Letter which included information on a high potential treatment for critical virus based diseases. Technology partner Mannin Research Inc. (Mannin) was recently granted up to $7.7 million in Europe, which will fund 65 percent of every dollar incurred to advance a portfolio of therapeutic assets for vascular diseases currently in development at Mannin, including: glaucoma, cardiovascular diseases, acute kidney disease, and infectious diseases such as influenza and coronavirus, among others.

Given the urgent need for therapeutics to treat COVID-19, Mannin is rapidly accelerating the time to the first clinical milestone for MAN-19. An Investigational New Drug (IND) application (or similar clinical trial proposal) to regulators are planned for late 2020. It is important to note that the MAN-19 therapeutic is virus-agnostic, which makes it relevant to other viral diseases today like influenza and future viral pandemic outbreaks. Therefore, a successful infectious disease application in COVID-19 would position MAN-19 very well as a potential government stockpile drug for inevitable future pandemics. Furthermore, a successful proof-of-concept clinical trial with MAN-19 in COVID-19 patients would provide the clinical dataset to quickly support the development of therapeutics for other vascular diseases such as sepsis, acute kidney injury, and of course glaucoma. All of these are very large markets with significant potential.

For more information on Q BioMed, Inc. (QBIO) visit: 

  • First exclusive implementer of U.S. Bank’s PowerTrack service, from first transaction to world’s largest transportation payment processing service.
  • First to implement an enterprise wide payment system within the U.S. Department of Defense.
  • First to design, develop, and host an independent MasterCard-branded system outside of the MasterCard IT infrastructure.
  • Implemented a financial transaction reconciliation solution within the U.S. Department of Homeland Security (U.S. Coast Guard).
  • Multiple Recent Acquisitions Including Adaptive Metadata Solutions with immediate high revenues projected.

Xalles Holdings Inc. (OTC: XALL) is a holding company that focuses on acquisition and support of disruptive financial services and technology (fintech) companies. XALL actively seeks targets in which it can partner with or acquire to accelerate growth, targeting companies with solid management teams and business models, large total attainable markets, and lucrative exit opportunities. XALL places emphasis on leveraging blockchain technologies to provide industry-leading financial reconciliation and auditing solutions, which, over time, will allow for the capture of recurring revenue streams.

  • Xalles Enters Global Metadata Management Business with 100% Acquisition of Adaptive Metadata Solutions

On July 21st XALL announced that it has executed a Share Exchange Agreement to acquire 100% of Adaptive Metadata Solutions Inc. (“Adaptive”). Adaptive Metadata Solutions is a Master Reseller of Adaptive products and provides industry leading metadata analytics (data that describes other data), and artificial intelligence solutions to large enterprises. 

Adaptive provides Fortune 500 clients with essential software solutions that deliver a business discipline of data governance, control and innovation to the enterprise. Industries currently serviced include Insurance, Financial Services, Government Agencies, Healthcare, Energy, and many other regulated industries, where compliance and data governance are critical to operational and strategic success.  New XALL acquisition Adaptive is projected to generate at least $5 million in 2020 revenue and more than $10 million in revenue in 2021.

The XALL Adaptive product suite is used by clients that include Bank of America, Federal Reserve Bank of New York, Western Union, the U.S. Government’s General Accounting Office (GAO), Dell, United Natural Foods, and numerous central banks and financial services companies.  

XALL has also completed multiple other recent high value acquisitions as follows:

1Rivet Global, through its proprietary 1Rivet PublicWorks Platform “1RPP”TM provides eGovernment and payment services to developing and emerging markets. 1Rivet Global will continue to focus its short-term sales and deployment efforts in Africa.

Argus has a network of sales channels and representatives which will be utilized to expand the sales reach of the recently acquired XALL companies, including MinervaWorks and Intel365. It is expected that Argus will provide marketing and sales services for new technology-based acquisitions within the XALL structure of companies.

Intel365 is a background check technology and services company that is a provider of employment background checks that includes drug testing, criminal record checks, education, and employment verification, reference checks, driving records, credit reports, social security trace and address history, civil court records, global background checks, sanctions, and risk reports.

MinervaWorks is a technology company that focuses on The Brick application, Managed Services and IT Consulting.  The Brick is a piece of hardware installed on a customer’s network, that analyzes the technology infrastructure, including end-user computing, systems, networks and cybersecurity The Brick is cloud enabled and virtualized, and utilizes proprietary edge computing platforms. 

  • Expansion of Cryptocurrency Strategy

On June 9th XALL announced that it has expanded its cryptocurrency and token strategies through a multi-pronged approach. One key goal is to build a portfolio of cryptocurrency assets ranging from Bitcoin (BTC) and Ethereum (ETH) to other alt coins. XALL will leverage a relationship with Vigor Crypto Holdings, LLC, a boutique cryptocurrency advisory firm, for the purchase of specific crypto assets as well as expert personnel to help manage the cryptocurrency trading process. XALL will look to creatively acquire these assets, in some cases in exchange for XALL restricted shares, and then grow the coin value through various trading strategies, which will be reflected in the balance sheet.

For more information on Xalles Holdings Inc. (XALL) visit:


Nightfood, Inc. (OTCQB: NGTF), the better-for-you snack company targeting the $50 billion consumers spend on nighttime snacks, and the Official Ice Cream of the American Pregnancy Association, announced today that Jennifer Mitchell, former North American CEO of leading baby products company MAM, has joined Nightfood in a full-time capacity as Chief Operating Officer and National Sales Director.

Mitchell spent over four years as CEO of North America at MAM, a leading international baby products company which is the global and United States market share leader in pacifiers.  Mitchell has worked extensively with major retailers such as Walmart, Target, Amazon, Buy Buy Baby, CVS, Walgreens, and Publix, and directly managed sales relationships with these chains.


Nightfood Ice Cream, (Stock Symbol: NGTF) Entering Pacific Northwest and New York Metro Markets

NGTF, the Official Ice Cream of the American Pregnancy Association which is addressing the $50 billion consumers spend on nighttime snacks, announced today that distribution is moving forward in both the Pacific Northwest and the New York City markets.

The two new grocery groups combine to represent over 300 supermarkets, and bring Nightfood to two of the largest metropolitan areas in the country:  New York Metro, and Seattle-Tacoma-Bellevue.  Nightfood is expected to start appearing on shelves in both regions in late July or early August, and the identity of the retailers will be shared as soon as management has the approval of the retail partners to make such information public.

NGTF also:

  • Ø The American Pregnancy Association Now Recommends Only Nightfood Ice Cream for Pregnant Women.
  • Ø Formulated with Less Sugar, Lower Fat, and Fewer Calories…Plus Minerals, Digestive Enzymes and Amino Acids for Better Sleep.
  • Ø CEO and Largest Shareholder Extends Lock-Up Agreement. 
  • Ø Nightfood Featured Nationally on the Rachael Ray Show, The Today Show, Oprah Magazine, Wall Street Journal and More.
  • Ø New Distribution in Major Divisions of Both Kroger and Albertsons, Two Largest Supermarkets in the U.S. Other Supermarkets Also Added.

Unhealthy nighttime snacking has become a major problem for over 100,000,000 Americans…Humans are biologically programmed to crave junk at night. For millions, ice cream is the #1 choice. Over 80% of Americans snack regularly at night, combining to spend over $1B on nighttime snacks every week.  A recent Harris Poll indicated most night snackers feel both guilty and out of control.

Nightfood (OTC: NGTF) is the fast-growing brand pioneering what experts project to be a multi-billion-dollar consumer category: sleep-friendly night snacking

After winning the prestigious 2019 Product of the Year award in the ice cream category in a Kantar survey of over 40,000 consumers, Nightfood also won the 2019 World Dairy Innovation Award as Best New Ice Cream.  


  • Nightfood Receives Endorsement as the Official Ice Cream of the American Pregnancy Association - Pregnancy Care Providers Begin Recommending Nightfood for its Unique Nutritional Profile

On February 20th NGTF announced that Nightfood ice cream is now formally being recommended as the Official Ice Cream of the American Pregnancy Association. The APA serves over five million women and families a month through their website and helpline and is recommending any pregnant women with ice cream cravings should eat Nightfood because of its many prenatal health benefits, making it a better choice for both mom and baby.

Over 10,000 new women enter the pregnancy demographic daily, proactively looking to make healthy lifestyle changes.  Ice cream is the #1 pregnancy craving.  Management believes this endorsement will accelerate sales velocity growth, and help secure thousands of additional points of supermarket distribution.

  • Busiest E-Commerce Day After National Feature on The Rachael Ray Show

On February 24th Nightfood ice cream was featured nationally on the Rachael Ray Show. As a result, the NGTF website was overwhelmed with traffic and the company was inundated with orders and local supermarket product requests. The Rachael Ray segment may be re-viewed at any time on The Rachael Ray website.

  • Distribution Secured in Albertsons Jewel-Osco Supermarket Chain with 188 Stores, Q1 Supermarket Sales Highest in Company History

On February 27th NGTF announced Nightfood ice cream will be available in all Jewel-Osco supermarket locations. This major Albertsons division has 188 locations encompassing Illinois, Northwest Indiana and Iowa.  On March 09th NGTF announced a sharp increase in recent supermarket reorder velocity resulting in a record quarter for sales.

In addition to Jewel-Osco, the brand will be available in two other major regional chains in the coming weeks, one of which will stock seven flavors in most of their 150+ stores.  The other new chain is expected to start with three or four flavors of Nightfood.  Harris Teeter, a division of Kroger, has seven Nightfood flavors available in most of their approximately 260 stores, and Lowe’s Foods has four flavors available in each of their 79 stores.

  • Nightfood Q1 Supermarket Sales Highest in Company History

On March 9th NGTF announced a sharp increase in recent supermarket reorders. For the week ending March 6th, orders were received for twelve pallets of product, almost all of it to refill existing retail partners. Each pallet contains approximately 2,000 pints of Nightfood ice cream.  This has been a record quarter for supermarket reorder volume. In addition, a significant amount of product has been shipped to distributors and wholesalers for new supermarket chains adding Nightfood. 

  • Nightfood Announces Distribution in Second Albertsons Division:  Shaw’s and Star Markets, Throughout New England

On March 26th NGTF management announced that Nightfood ice cream is now available in Shaw’s and Star Market locations. A division of Albertsons Companies, one of the largest food and drug retailers in the United States, Shaw’s and Star Markets operates over 150 stores through most of New England, including Massachusetts, New Hampshire, Vermont, Maine, and Rhode Island.  

For more information on NGTF visit:


  • GDMK is a well Established Food Producer Serving North American & Europe.
  • Sales have Soared 151 Percent in the Last 30 Days Exceeding Expectations with an Increase of Over 451 Percent in the Last 12 Months
  • GDMK partners with Ruttensteiner to distribute its folio of products in Austria and European Union markets.
  • Relationships include Lidl, Hofer, Spar, Rewe Austria, Migros and Aldi
  • Signed Agreement with Distribution Partner, Grocery Outlet, an Emerging High-Growth Industry Leader.
  • New Secured Distribution to Bring Premium Food Products into Homes Throughout the USA.   
  • Attractive Share Structure with Only 13 Million OS. 
  • GDMK Secures New Distribution by Expanding into Restaurant Depot Stores Nationwide

Global Diversified Marketing Group, Inc. (OTC: GDMK) operates as a food and snack manufacturer, Importer & distributor through its subsidiary in the United States, Canada, and Europe. The company operates through Snack segments. The Snack segment offers Italian Wafers, Italian Filled Croissants, French Madeleines, Wafer Pralines, Shelf Stable Macarons and other gourmet snacks. GDMK sells its products direct and through various distribution channels comprising specialty, grocery retailers and food-service distributors, DSD as well as vending, pantry and micro market segment.

GDMK is a fully reporting OTC listed company with a small share structure of only about 13 million shares outstanding. The company has also qualified for the Verified Profile and Transfer Agent Verified designations at

  • Growth Opportunities Through Expanding and Securing New Distribution Venues with Over 350 Grocery Outlet Locations

On April 23rd GDMK announced that it has secured distribution with Grocery Outlet to strengthen the company’s brand and bring its Premium Biscottelli product line into an untapped segment of the consumer market through an advantageous partnership with this emerging grocery industry leader. Grocery Outlet owns and operates a chain of grocery stores in the United States. As of December 28, 2019, Grocery Outlet had 347 stores, which included 342 independent operated stores and 5 company operated stores in California, Washington, Oregon, Pennsylvania, Idaho, and Nevada.

The GDMK Biscottelli segment is a high-growth, extreme value retailer of quality, name-brand consumables and fresh products, and relies on an "opportunistic buying" strategy to secure items from suppliers, many of whom are the country's top consumer product and food manufacturers.

Today’s marketplace is swiftly evolving. The new relationship between GDMK and Grocery Outlet is expected to thrive even in the midst of challenging times, whereas there is a strong common denominator in how the future is perceived. While the nation operates at an average 30% capacity, Grocery Outlet holds to a recognized opportunistic philosophy that treats roadblocks as milestones, and converts adversity to opportunity, by staying ahead of the curve.

According to, “Grocery Outlet is capitalizing on shoppers stockpiling groceries during the outbreak and the havoc across supply chains. The report stated: “The coronavirus is crippling most American industries. But it's also creating opportunities for some unexpected businesses. Grocery Outlet's business model is a lot like TJX (TJX), the parent company of T.J.Maxx, Marshalls, HomeGoods. This may put it in a strong position to succeed during the crisis and beyond, analysts say."

According to the CNN review, “There's a huge amount of supply chain disruption going around right now, and this imbalance between supply and demand is a positive for Grocery Outlet's business."  This situation should give GDMK products a significant boost in sales for 2020 or longer. 

For more information on GDMK visit the company’s website at:


  • Well Established Healthcare Provider Offering Personalized Service.
  • Multiple Subsidiaries Generating Strong and Growing Revenues.
  • Net Revenues for the Last 6 Months Totaled $18.3 Million.
  • Strong Balance Sheet with Over $2 Million in Cash.  
  • Significant Business Expansions and Rapid Covid Testing Services.

Progressive Care Inc. (OTCQB: RXMD), through its subsidiaries, is a personalized healthcare services and technology company which provides prescription pharmaceutical services including Covid-testing, risk management and data analytics to healthcare organizations and providers.

RXMD seeks to define a new level of service and healthcare that is driven by the needs of patients and families. As the healthcare system changes and adjusts, gaps form in the delivery of care leaving patients, providers, and even payors behind to deal with negative health outcomes. RXMD works to eliminate obstacles and inadequacies in care by delivering innovative, patient-centric services that improve the health and well-being of our communities.

  • Q2 2020 Financials: Sales Up 32%, Over $2M in Cash on Hand

On August 17th RXMD announced operational performance data for the three months and six months ended June 30, 2020. Highlights included the following milestones:

  • Consolidated net revenues for the three months ended June 30 totaled $9.2 million (for the six months ended June 30, $18.3 million), representing year-over-year growth of 32% (and 50% for the six-month period) compared to comparable periods in 2019
  • Prescriptions filled in Q2 topped 126,000 (and 258,000 in the six-month period), representing year-over-year growth of 23% in Q2 2020 (and 38% for the six-month period) compared to comparable periods in 2019
  • Income from services related to 340B Covered Entities increased over $420,000 compared to the previous six-month period, a 191% increase (314% increase in Q2 2020, quarter-over-quarter) totaling $640,000 
  • Strong Cash position, boosted to over $2 million during Q2 2020
  • Positive cash flow from operations of over $764,000 for the six months ended June 30th, 2020

These results highlight strong net gains in new patients and new healthcare organizations and providers since March as RXMD takes up the mantle as the leader in COVID-19 measures in the pharmacy services space, including free contactless same-day prescription delivery, in-store social distancing through headcount shift planning, and antibody testing.

RXMD is focused on driving robust growth in the second half of the year from traditional pharmacy services, but management anticipates a materially increasing impact from health data analytics as it accelerates the development in its new ClearMetRx platform, the RXMD wholly-owned data analytics company with services designed to support health care organizations across the country. The company has unique expertise in health data analytics and data management and has begun to market these services to healthcare entities. Continued development of automated systems and digital assets to support these data-driven products and services is expected to drive future revenue and profitability growth.

The impact of health data analytics services can be seen in connection with the RXMD role serving as a Third-Party Administrator for a growing number of 340B eligible clients. For the three months ended June 30, RXMD saw total sales related to 340B clients jump 314% on a year-over-year basis. 

RXMD recently commenced construction on the build-out of its 400 Ansin Blvd. building in Q2 2020. The purchased facility in Hallandale Beach has over 11,000 square feet and will house the operations of both the North Miami Beach and Davie, FL locations. The transition of operations from leased space will result in nearly $300,000 in savings in 2021. RXMD plans to keep a portion of its North Miami Beach location to support its growing e-commerce and retail health products division.

  • Significant Expansion to Establish Full-Service PharmCo Operations and Rapid Covid Testing Services in Orlando Regional Market

On July 29th RXMD announced expansion of its PharmCo branded pharmacy operations and presence in the Orlando metropolitan area. RXMD is moving out of its current Orlando pharmacy location, which is a 700 square-foot mini-pharmacy operating under the “Five Star” brand designation, to a 3,700 square-foot full-size pharmacy that will open under the PharmCo brand designation. The move, which represents an expansion in property size of more than 400%, will not increase monthly lease costs.

This move will also allow for a dramatic expansion in the RXMD services and products offered in the Orlando market, including the full scope of PharmCo pharmacy goods and services, as well as therapy management, patient management, cost management services, and rapid-results testing services (COVID-19 IgG/IgM) as authorized by the FDA under its Emergency Use Authorization (“EUA”) guidelines for conducting SARS-CoV-2 antibody presence and COVID-19 infection diagnosis testing.

For more information on Progressive Care, Inc. (RXMD) visit:



WinPlay announces decentralized token sale in order to pass control overtheir platform over to their 450K registered users and serious investors.

The platform is a gamified marketing platform that has been live and building
crypto communities for over a year. These communities include now successful
projects like Nimiq, Swipe, Casper Labs, WhiteBit Exchange, KuCoin Exchange and
BiKi Exchange just to name a few.

WinPlay released their decentralization plansin a manifesto. In their visionstatement they explain that the main reason behind this decentralized working
model is to ‘ ...create immense amounts of wealthfor all WinPlay participants without a centralized overseer.”

You can read the announcement at length and participate in their launch
campaign here:

WinPlay has a strong and numerouscommunity to support them and a working product live at:

Interest in cryptocurrencies is again at an all time high due to the many foes
about the economy. More and more projects like WinPlay are choosing to move
into trustless and decentralized methods of collaboration, and it seems to be

The blockchain space has received a new wave of mainstream interest thanks to
the development of Decentralized Defi protocols that are disrupting the
financial industry faster than anything that has come before it.

What is Defi and Why is Growing So Fast?

Decentralized finance is quickly becoming the fastest growing trend in the
financial industry.

Allowing any user in the world to lend, borrow, deposit and participate in
complex financial products without asking anyone (like a bank or regulator) for
permission or even needing to open an account is shaping the way global
investors think about opportunities.

The total amount of resources locked in Defi products has surpassed 4 billion
USD, up from about 2 Billion last month. The entire Defi ecosystem is sucking
up financial resources from all industries as this new gold rush bull cycle

Tokenization of Everything

With the growing interest of investors and developers in this new environment,
projects are sprouting everywhere again in an attempt to best use Defi
protocols available in the market to keep building on this unstoppable network.

Ethereum andother growing cryptocurrency networks are locked in a head to head race to
decentralize our world and it is guaranteed that WinPlay will not be the last
project diving fully into the Defi DAO ecosystem.




Here and now, I give you my word: If you entrust me with the presidency, I will draw on the best of us, not the worst. I will be an ally of the light, not of the darkness.

It’s time for us, for We the People, to come together.

For make no mistake. United we can, and will, overcome this season of darkness in America. We will choose hope over fear, facts over fiction, fairness over privilege.

I am a proud Democrat, and I will be proud to carry the banner of our party into the general election. So, it is with great honor and humility that I accept this nomination for President of the United States of America.
Here and now, I give you my word: If you entrust me with the presidency, I will draw on the best of us, not the worst. I will be an ally of the light, not of the darkness.

It’s time for us, for We the People, to come together.

For make no mistake. United we can, and will, overcome this season of darkness in America. We will choose hope over fear, facts over fiction, fairness over privilege.

I am a proud Democrat, and I will be proud to carry the banner of our party into the general election. So, it is with great honor and humility that I accept this nomination for President of the United States of America.

Here and now, I give you my word: If you entrust me with the presidency, I will draw on the best of us, not the worst. I will be an ally of the light, not of the darkness.

It’s time for us, for We the People, to come together.

For make no mistake. United we can, and will, overcome this season of darkness in America. We will choose hope over fear, facts over fiction, fairness over privilege.

I am a proud Democrat, and I will be proud to carry the banner of our party into the general election. So, it is with great honor and humility that I accept this nomination for President of the United States of America.

Get more information, please visit


Gurpreet Singh is an American-India Singer. His stage name is Luxy Singh (IG: @luxysing). His origins are from Punjab, but nowadays, he lives in San Francisco, California. The artist started his career in 2011, and had an interest in American Indian Music. He has been in the industry for nine years now and he plans on dropping his debut single soon. Wealthy, Charismatic, and Smart, he did his education in California, USA.

Mr. Singh went to SAE Expressions to study sound engineering, which is one of the best digital media schools in the United States of America. Additionally, now at the age of 27, he already owns his own record label “SlumdoggMillionairez Productions”. With high ambitions and great courage, his team is about to shoot the next video for the song “One Kiss” in Las Vegas. Not only he is working with big labels from America, but also from India.

Get more information, please visit